279 related articles for article (PubMed ID: 20959519)
41. Barrett's: do we still need goblet cells for diagnosis?
Lenglinger J; Riegler M
Am J Gastroenterol; 2009 Sep; 104(9):2355-6; author reply 2356-7. PubMed ID: 19727095
[No Abstract] [Full Text] [Related]
42. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
[TBL] [Abstract][Full Text] [Related]
43. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
[TBL] [Abstract][Full Text] [Related]
44. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization.
van Dekken H; Vissers CJ; Tilanus HW; Tanke HJ; Rosenberg C
J Pathol; 1999 Jul; 188(3):263-6. PubMed ID: 10419593
[TBL] [Abstract][Full Text] [Related]
45. In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line.
Morgan C; Alazawi W; Sirieix P; Freeman T; Coleman N; Fitzgerald R
Am J Gastroenterol; 2004 Feb; 99(2):218-24. PubMed ID: 15046208
[TBL] [Abstract][Full Text] [Related]
46. Neoplastic risk assessment in Barrett's esophagus: How far have we come?
Noffsinger A
Hum Pathol; 2003 Oct; 34(10):965-7. PubMed ID: 14608528
[No Abstract] [Full Text] [Related]
47. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
[TBL] [Abstract][Full Text] [Related]
48. Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples.
van Nistelrooij AM; van Marion R; Koppert LB; Biermann K; Spaander MC; Tilanus HW; van Lanschot JJ; Wijnhoven BP; Dinjens WN
BMC Res Notes; 2017 Apr; 10(1):144. PubMed ID: 28376920
[TBL] [Abstract][Full Text] [Related]
49. Molecular targets for treatment of Barrett's esophagus.
Feagins LA; Souza RF
Dis Esophagus; 2005; 18(2):75-86. PubMed ID: 16053481
[TBL] [Abstract][Full Text] [Related]
50. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of the cyclin D1 gene in Barrett's esophagus.
Arber N; Lightdale C; Rotterdam H; Han KH; Sgambato A; Yap E; Ahsan H; Finegold J; Stevens PD; Green PH; Hibshoosh H; Neugut AI; Holt PR; Weinstein IB
Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):457-9. PubMed ID: 8781742
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium.
Drahos J; Schwameis K; Orzolek LD; Hao H; Birner P; Taylor PR; Pfeiffer RM; Schoppmann SF; Cook MB
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):429-37. PubMed ID: 26604271
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.
Soldes OS; Kuick RD; Thompson IA; Hughes SJ; Orringer MB; Iannettoni MD; Hanash SM; Beer DG
Br J Cancer; 1999 Feb; 79(3-4):595-603. PubMed ID: 10027336
[TBL] [Abstract][Full Text] [Related]
54. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
55. [Demonstration of clonal heterogeneity in adenocarcinomas on Barrett's esophagus by flow cytometric study of cellular DNA content].
Robaszkiewicz M; Volant A; Hardy E; Nousbaum JB; Calament G; Cauvin JM; Bail JP; Lozach P; Gouerou H
Gastroenterol Clin Biol; 1992; 16(6-7):540-6. PubMed ID: 1526415
[TBL] [Abstract][Full Text] [Related]
56. ROLE OF MICRORNA IN PREDICTING OF ADENOCARCINOMA DEVELOPMENT IN BARRETT’S ESOPHAGUS.
Tsitskarava AZ; Zaraiskiy MI; Vasilevskiy DI; Lapshin AS; Popova VF; Smirnov AA; Lyubchenko ME
Vestn Khir Im I I Grek; 2016; 175(4):13-4. PubMed ID: 30457256
[TBL] [Abstract][Full Text] [Related]
57. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
[TBL] [Abstract][Full Text] [Related]
58. The molecular basis of carcinogenesis in Barrett's esophagus.
Souza RF
J Gastrointest Surg; 2010 Jun; 14(6):937-40. PubMed ID: 20094816
[No Abstract] [Full Text] [Related]
59. APC gene alterations in Barrett's metaplasia are implicated at an early stage in the carcinogenesis of esophageal adenocarcinoma.
Fein M
Am J Gastroenterol; 1997 Feb; 92(2):359-60. PubMed ID: 9040229
[No Abstract] [Full Text] [Related]
60. Barrett's oesophagus: from metaplasia to dysplasia and cancer.
Fléjou JF
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
